The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients

Nephrology Dialysis Transplantation

Volumn 29, Issue 2, 2014, Pages 263-273

  Zumbrennen Bullough, Kimberly ^a   Babitt, Jodie L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

anemia; chronic kidney disease; hepcidin; iron; review

Indexed keywords

ANTIANEMIC AGENT; BONE MORPHOGENETIC PROTEIN; CD71 ANTIGEN; FERROPORTIN; HEMOJUVELIN; HEPARIN; HEPCIDIN; HFE PROTEIN; IRON; LDN 193189; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; RECEPTOR BLOCKING AGENT; SILTUXIMAB; SMAD PROTEIN; TOCILIZUMAB; TRANSFERRIN RECEPTOR 2; UNCLASSIFIED DRUG;

ANEMIA; CELL HYPOXIA; CHRONIC KIDNEY DISEASE; DRUG SAFETY; ERYTHROPOIESIS; GASTROINTESTINAL SYMPTOM; HEMOCHROMATOSIS; HEMODIALYSIS; HJV GENE; HORMONAL REGULATION; HUMAN; INFLAMMATION; IRON ABSORPTION; IRON BALANCE; IRON DEFICIENCY ANEMIA; IRON INTAKE; IRON METABOLISM; IRON OVERLOAD; IRON THERAPY; IRON TRANSPORT; NONHUMAN; NUTRITIONAL STATUS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETICULOCYTE HEMOGLOBIN CONTENT; REVIEW;

ANEMIA; CHRONIC KIDNEY DISEASE; HEPCIDIN; IRON; REVIEW;

ANEMIA, IRON-DEFICIENCY; ANIMALS; DISEASE PROGRESSION; DNA; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HEPCIDINS; HOMEOSTASIS; HUMANS; IRON; MODELS, THEORETICAL; RENAL INSUFFICIENCY, CHRONIC;

EID: 84896733066     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft443     Document Type: Review

References (164)

1. Hentze MW, Muckenthaler MU, Andrews NC. Balancing acts: Molecular control of mammalian iron metabolism. Cell 2004; 117: 285-297
2. Kovac S, Anderson GJ, Baldwin GS. Gastrins, iron homeostasis and colorectal cancer. Biochim Biophys Acta 2011; 1813: 889-895
3. McKie AT, Barrow D, Latunde-Dada GO et al. An iron-regulated ferric reductase associated with the absorption of dietary iron. Science 2001; 291: 1755-1759
4. Gunshin H, Starr CN, Direnzo C et al. Cybrd1(duodenal cytochrome b) is not necessary for dietary iron absorption in mice. Blood 2005; 16: 16
5. Fleming MD, Trenor CC, III, Su MA et al. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat Genet 1997; 16: 383-386
6. Gunshin H, Mackenzie B, Berger UV et al. Cloning and characterization of a mammalian proton-ion transporter. Nature 1997; 388: 482-488
7. Gunshin H, Fujiwara Y, Custodio AO et al. Slc11a2 is required for intestinal iron absorption and erythropoiesis but dispensable in placenta and liver. J Clin Invest 2005; 115: 1258-1266
8. Weintraub LR,Weinstein MB, Huser HJ et al. Absorption of hemoglobin iron: The role of a heme-splitting substance in the intestinal mucosa. J Clin Invest 1968; 47: 531-539
9. Donovan A, Brownlie A, Zhou Y et al. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature 2000; 403: 776-781
10. Abboud S, Haile DJ. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem 2000; 275: 19906-19912
11. McKie AT, Marciani P, Rolfs A et al. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell 2000; 5: 299-309
12. Osaki S, Johnson DA. Mobilization of liver iron by ferroxidase (ceruloplasmin). J Biol Chem 1969; 244: 5757-5758
13. Osaki S, Johnson DA, Frieden E. The possible significance of the ferrous oxidase activity of ceruloplasmin in normal human serum. J Biol Chem 1966; 241: 2746-2751
14. Roeser HP, Lee GR, Nacht S et al. The role of ceruloplasmin in iron metabolism. J Clin Invest 1970; 49: 2408-2417
15. Vulpe CD, Kuo YM, Murphy TL et al. Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. Nat Genet 1999; 21: 195-199
16. Krause A, Neitz S, Mägert HJ et al. LEAP-1, a novel highly disulfidebonded human peptide, exhibits antimicrobial activity. FEBS Lett 2000; 480: 147-150
17. Pigeon C, Ilyin G, Courselaud B et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001; 276: 7811-7819
18. Park CH, Valore EV, Waring AJ et al. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001; 276: 7806-7810
19. Nicolas G, Bennoun M, Devaux I et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci USA 2001; 98: 8780-8785
20. Lesbordes-Brion JC, Viatte L, Bennoun M et al. Targeted disruption of the hepcidin 1 gene results in severe hemochromatosis. Blood 2006; 108: 1402-1405
21. Roetto A, Papanikolaou G, Politou M et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 2003; 33: 21-22
22. Nicolas G, Bennoun M, Porteu A et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci USA 2002; 99: 4596-4601
23. Weinstein DA, Roy CN, Fleming MD et al. Inappropriate expression of hepcidin is associated with iron refractory anemia: Implications for the anemia of chronic disease. Blood 2002; 100: 3776-3781
24. Nemeth E, Tuttle MS, Powelson J et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306: 2090-2093
25. Mastrogiannaki M, Matak P, Peyssonnaux C. The gut in iron homeostasis: Role of HIF-2 under normal and pathological conditions. Blood 2013; doi:10.1182/blood-2012-11-427765
26. Nicolas G, Chauvet C, Viatte L et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002; 110: 1037-1044
27. Nemeth E, Rivera S, Gabayan V et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113: 1271-1276
28. Nemeth E, Valore EV, Territo M et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003; 101: 2461-2463
29. Armitage AE, Eddowes LA, Gileadi U et al. Hepcidin regulation by innate immune and infectious stimuli. Blood 2011; 118: 4129-4139
30. Drakesmith H, Prentice AM. Hepcidin and the iron-infection axis. Science 2012; 338: 768-772
31. Sun CC, Vaja V, Babitt JL et al. Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol 2012; 87: 392-400
32. Goodnough JB, Ramos E, Nemeth E et al. Inhibition of hepcidin transcription by growth factors. Hepatology 2012; 56: 291-299
33. Yang Q, Jian J, Katz S et al. 17β-estradiol inhibits iron hormone hepcidin through an estrogen responsive element half-site. Endocrinology 2012; 153: 3170-3178
34. Hou Y, Zhang S, Wang L et al. Estrogen regulates iron homeostasis through governing hepatic hepcidin expression via an estrogen response element. Gene 2012; 511: 398-403
35. GuoW, Bachman E, Li Met al. Testosterone administration inhibits hepcidin transcription and is associated with increased iron incorporation into red blood cells. Aging Cell 2013; 12: 280-291
36. Latour C, Kautz L, Besson-Fournier C et al. Testosterone perturbs systemic iron balance through activation of EGFR signaling in the liver and repression of hepcidin. Hepatology 2013. doi:10.1002/hep.26648
37. Babitt JL, Lin HY. The molecular pathogenesis of hereditary hemochromatosis. Semin Liver Dis 2011; 31: 280-292
38. Papanikolaou G, Samuels ME, Ludwig EH et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 2004; 36: 77-82
39. Babitt JL, Huang FW, Wrighting DM et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 2006; 38: 531-539
40. Corradini E, Meynard D, Wu Q et al. Serum and liver iron differently regulate the bone morphogenetic protein 6 (BMP6)-SMAD signaling pathway in mice. Hepatology 2011; 54: 273-284
41. Yu PB, Hong CC, Sachidanandan C et al. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol 2008; 4: 33-41
42. Corradini E, Babitt JL, Lin HY. The RGM/DRAGON family of BMP coreceptors. Cytokine Growth Factor Rev 2009; 20: 389-398
43. Huang FW, Pinkus JL, Pinkus GS et al. A mouse model of juvenile hemochromatosis. J Clin Invest 2005; 115: 2187-2191
44. Niederkofler V, Salie R, Arber S. Hemojuvelin is essential for dietary iron sensing, and its mutation leads to severe iron overload. J Clin Invest 2005; 115: 2180-2186
45. Andriopoulos B, Jr, Corradini E, Xia Y et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet 2009; 41: 482-487
46. Meynard D, Kautz L, Darnaud V et al. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet 2009; 41: 478-481
47. Wu Q, Sun CC, Lin HY et al. Repulsive guidance molecule (RGM) family proteins exhibit differential binding kinetics for bone morphogenetic proteins (BMPs). PLoS One 2012; 7: E46307
48. Xia Y, Babitt JL, Sidis Y et al. Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin. Blood 2008; 111: 5195-5204
49. Steinbicker AU, Bartnikas TB, Lohmeyer LK et al. Perturbation of hepcidin expression by BMP type I receptor deletion induces iron overload in mice. Blood 2011; 118: 4224-4230
50. Kawabata H, Yang R, Hirama T et al. Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like family. J Biol Chem 1999; 274: 20826-20832
51. West AP, Jr, Bennett MJ, Sellers VM et al. Comparison of the interactions of transferrin receptor and transferrin receptor 2 with transferrin and the hereditary hemochromatosis protein HFE. J Biol Chem 2000; 275: 38135-38138
52. Feder JN, Penny DM, Irrinki A et al. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci USA 1998; 95: 1472-1477
53. Lebrón JA, West AP, Jr, Bjorkman PJ. The hemochromatosis protein HFE competes with transferrin for binding to the transferrin receptor. J Mol Biol 1999; 294: 239-245
54. West AP, Jr, Giannetti AM, Herr AB et al. Mutational analysis of the transferrin receptor reveals overlapping HFE and transferrin binding sites. J Mol Biol 2001; 313: 385-397
55. Giannetti AM, Björkman PJ. HFE and transferrin directly compete for transferrin receptor in solution and at the cell surface. J Biol Chem 2004; 279: 25866-25875
56. Goswami T, Andrews NC. Hereditary hemochromatosis protein, HFE, interaction with transferrin receptor 2 suggests a molecular mechanism for mammalian iron sensing. J Biol Chem 2006; 281: 28494-28498
57. Gao J, Chen J, Kramer M et al. Interaction of the hereditary hemochromatosis protein HFE with transferrin receptor 2 is required for transferrin-induced hepcidin expression. Cell Metab 2009; 9: 217-227
58. D'Alessio F, HentzeMW, Muckenthaler MU. The hemochromatosis proteins HFE, TfR2, and HJV form a membrane-Associated protein complex for hepcidin regulation. J Hepatol 2012; 57: 1052-1060
59. Corradini E, Garuti C, Montosi G et al. Bone morphogenetic protein signaling is impaired in a Hfe knockout mouse model of hemochromatosis. Gastroenterology 2009; 137: 1489-1497
60. Kautz L, Meynard D, Besson-Fournier C et al. BMP/Smad signaling is not enhanced in Hfe-deficient mice despite increased Bmp6 expression. Blood 2009; 114: 2515-2520
61. Wallace DF, Summerville L, Crampton EM et al. Combined deletion of Hfe and transferrin receptor 2 in mice leads to marked dysregulation of hepcidin and iron overload. Hepatology 2009; 50: 1992-2000
62. Bolondi G, Garuti C, Corradini E et al. Altered hepatic BMP signaling pathway in human HFE hemochromatosis. Blood Cells Mol Dis 2010; 45: 308-312
63. Ryan JD, Ryan E, Fabre A et al. Defective bone morphogenic protein signaling underlies hepcidin deficiency in HFE hereditary hemochromatosis. Hepatology 2010; 52: 1266-1273
64. Corradini E, Rozier M, Meynard D et al. Iron regulation of hepcidin despite attenuated Smad1,5,8 signaling in mice without transferrin receptor 2 or Hfe. Gastroenterology 2011; 141: 1907-1914
65. Pietrangelo A, Caleffi A, Henrion J et al. Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes. Gastroenterology 2005; 128: 470-479
66. Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood 2006; 108: 3204-3209
67. Verga Falzacappa MV, Vujic Spasic M, Kessler R et al. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood 2007; 109: 353-358
68. Pietrangelo A, Dierssen U, Valli L et al. STAT3 is required for IL-6-gp130 dependent activation of hepcidin in vivo. Gastroenterology 2007; 132: 294-300
69. Theurl I, Schroll A, Nairz Met al. Pathways for the regulation of hepcidin expression in anemia of chronic disease and iron deficiency anemia in vivo. Haematologica 2011; 96: 1761-1769
70. Besson-Fournier C, Latour C, Kautz L et al. Induction of activin B by inflammatory stimuli up-regulates expression of the iron-regulatory peptide hepcidin through Smad1/5/8 signaling. Blood 2012; 120: 431-439
71. Wang RH, Li C, Xu X et al. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab 2005; 2: 399-409
72. Babitt JL, Huang FW, Xia Y et al. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest 2007; 117: 1933-1939
73. Verga Falzacappa MV, Casanovas G, Hentze MWet al. A bone morphogenetic protein (BMP)-responsive element in the hepcidin promoter controls HFE2-mediated hepatic hepcidin expression and its response to IL-6 in cultured cells. J Mol Med 2008; 86: 531-540
74. Theurl I, Schroll A, Sonnweber T et al. Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats. Blood 2011; 118: 4977-4984
75. Steinbicker AU, Sachidanandan C, Vonner AJ et al. Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation. Blood 2011; 117: 4915-4923
76. Pak M, Lopez MA, Gabayan V et al. Suppression of hepcidin during anemia requires erythropoietic activity. Blood 2006; 108: 3730-3735
77. Vokurka M, Krijt J, Sulc K et al. Hepcidin mRNA levels in mouse liver respond to inhibition of erythropoiesis. Physiol Res 2006; 55: 667-674
78. Tanno T, Bhanu NV, Oneal PA et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007; 13: 1096-1101
79. Tanno T, Porayette P, Sripichai O et al. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood 2009; 114: 181-186
80. Casanovas G, Spasic MV, Casu C et al. The murine growth differentiation factor 15 is not essential for systemic iron homeostasis in phlebotomized mice. Haematologica 2013; 98: 444-447
81. Ashby DR, Gale DP, Busbridge M et al. Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica 2010; 95: 505-508
82. Liu Q, Davidoff O, Niss K et al. Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. J Clin Invest 2012; 122: 4635-4644
83. Mastrogiannaki M, Matak P, Mathieu JR et al. Hepatic hypoxia-inducible factor-2 down-regulates hepcidin expression in mice through an erythropoietin-mediated increase in erythropoiesis. Haematologica 2012; 97: 827-834
84. Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: Implications for the anemia of CKD. Am J Kidney Dis 2010; 55: 726-741
85. Finberg KE. Regulation of systemic iron homeostasis. Curr Opin Hematol 2013; 20: 208-214
86. Harrison-Findik DD. Gender-related variations in iron metabolism and liver diseases.World J Hepatol 2010; 2: 302-310
87. Bacchetta J, Zaritsky J, Lisse TS et al. Poster #FR-PO1560. Vitamin D as a new regulator of iron metabolism: Vitamin D suppresses hepcidin in vitro and in vivo. J Am Soc Nephrol 2011; 22: 474A\
88. Troutt JS, Rudling M, Persson L et al. Circulating human hepcidin-25 concentrations display a diurnal rhythm, increase with prolonged fasting, and are reduced by growth hormone administration. Clin Chem 2012; 58: 1225-1232
89. Aigner E, Felder TK, Oberkofler H et al. Glucose acts as a regulator of serum iron by increasing serum hepcidin concentrations. J Nutr Biochem 2013; 24: 112-117
90. Mircescu G, Garneata L, Capusa C et al. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients. Nephrol Dial Transplant 2006; 21: 120-124
91. Silverberg DS, Iaina A, Peer G et al. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis 1996; 27: 234-238
92. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995; 26: 41-46
93. Sunder-Plassmann G, Horl WH. Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 1995; 10: 2070-2076
94. Pisoni RL, Fuller DS, Bieber BA et al. The DOPPS practice monitor for US dialysis care: Trends through August 2011. Am J Kidney Dis 2012; 60: 160-165
95. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590
96. Singh AK, Szczech L, Tang KL et al.; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098
97. Pfeffer MA, Burdmann EA, Chen CY et al.; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032
98. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl 2012; 2: 279-335
99. Ganz T, Olbina G, Girelli D et al. Immunoassay for human serum hepcidin. Blood 2008; 112: 4292-4297
100. Ashby DR, Gale DP, Busbridge M et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 2009; 75: 976-981
101. Zaritsky J, Young B, Wang HJ et al. Hepcidin-A potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1051-1056
102. Coyne DW, Kapoian T, SukiWet al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV iron with elevated ferritin (DRIVE) Study. J Am Soc Nephrol 2007; 18: 975-984
103. Singh AK, Coyne DW, Shapiro W et al. Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation. Kidney Int 2007; 71: 1163-1171
104. Stancu S, Barsan L, Stanciu A et al. Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease?. Clin J Am Soc Nephrol 2010; 5: 409-416
105. Fishbane S, Kowalski EA, Imbriano LJ et al. The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol 1996; 7: 2654-2657
106. Locatelli F, Bárány P, Covic A et al.; ERA-EDTA ERBP Advisory Board. Kidney disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: A European Renal Best Practice position statement. Nephrol Dial Transplant 2013; 28: 1346-1359
107. Mittman N, Sreedhara R, Mushnick R et al. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO. Am J Kidney Dis 1997; 30: 912-922
108. Fishbane S, Galgano C, Langley RC, Jr et al. Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int 1997; 52:217-222
109. Fishbane S, Shapiro W, Dutka P et al. A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int 2001; 60: 2406-2411
110. Tessitore N, Solero GP, Lippi G et al. The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant 2001; 16:1416-1423
111. Mitsuiki K, Harada A, Miyata Y. Assessment of iron deficiency in chronic hemodialysis patients: Investigation of cutoff values for reticulocyte hemoglobin content. Clin Exp Nephrol 2003; 7: 52-57
112. Chuang CL, Liu RS, Wei YH et al. Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients. Nephrol Dial Transplant 2003; 18: 370-377
113. Bovy C, Gothot A, Delanaye P et al. Mature erythrocyte parameters as new markers of functional iron deficiency in haemodialysis: Sensitivity and specificity. Nephrol Dial Transplant 2007; 22: 1156-1162
114. Wish JB. Assessing iron status: Beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 2006; 1(Suppl. 1): S4-S8
115. Ahluwalia N, Skikne BS, Savin V et al. Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure. Am J Kidney Dis 1997; 30: 532-541
116. Kroot JJ, Kemna EH, Bansal SS et al. Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: Need for standardization. Haematologica 2009; 94: 1748-1752
117. Roe MA, Spinks C, Heath AL et al. Serum prohepcidin concentration: No association with iron absorption in healthy men; and no relationship with iron status in men carrying HFE mutations, hereditary haemochromatosis patients undergoing phlebotomy treatment, or pregnant women. Br J Nutr 2007; 97: 544-549
118. Kemna E, Pickkers P, Nemeth E et al. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood 2005; 106: 1864-1866
119. Van derWeerd NC, Grooteman MP, Bots ML et al.; CONTRAST Investigators. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents. PLoS One 2012; 7: E39783
120. Kato A, Tsuji T, Luo J et al. Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients. Am J Nephrol 2008; 28: 115-121
121. Zaritsky J, Young B, Gales B et al. Reduction of serum hepcidin by hemodialysis in pediatric and adult patients. Clin J Am Soc Nephrol 2010; 5: 1010-1014
122. Ford BA, Eby CS, Scott MG et al. Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients. Kidney Int 2010; 78: 769-773
123. Peters HP, Rumjon A, Bansal SS et al. Intra-individual variability of serum hepcidin-25 in haemodialysis patients using mass spectrometry and ELISA. Nephrol Dial Transplant 2012; 27: 3923-3929
124. Tessitore N, Girelli D, Campostrini N et al. Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrol Dial Transplant 2010; 25: 3996-4002
125. Brasse-Lagnel CG, Poli M, Lesueur C et al. Immunoassay for human serum hemojuvelin. Haematologica 2010; 95: 2031-2037
126. Finkenstedt A, Widschwendter A, Brasse-Lagnel CG et al. Hepcidin is correlated to soluble hemojuvelin but not to increased GDF15 during pregnancy. Blood Cells Mol Dis 2012; 48: 233-237
127. Luciani N, Brasse-Lagnel C, Poli M et al. Hemojuvelin: A new link between obesity and iron homeostasis. Obesity (Silver Spring) 2010; 19: 1545-1551
128. Rumjon A, Sarafidis P, Brincat S et al. Serum hemojuvelin and hepcidin levels in chronic kidney disease. Am J Nephrol 2012; 35: 295-304
129. Malyszko J, Malyszko JS, Levin-Iaina N et al. Is hemojuvelin a possible new player in iron metabolism in hemodialysis patients?. Int Urol Nephrol 2011; 44: 1805-1811
130. Silvestri L, Pagani A, Camaschella C. Furin-mediated release of soluble hemojuvelin: A new link between hypoxia and iron homeostasis. Blood 2008; 111: 924-931
131. Kuninger D, Kuns-Hashimoto R, Nili M et al. Pro-protein convertases control the maturation and processing of the iron-regulatory protein, RGMc/hemojuvelin. BMC Biochem 2008; 9: 9
132. Lin L, Nemeth E, Goodnough JB et al. Soluble hemojuvelin is released by proprotein convertase-mediated cleavage at a conserved polybasic RNRR site. Blood Cells Mol Dis 2008; 40: 122-131
133. Silvestri L, Pagani A, Nai A et al. The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab 2008; 8: 502-511
134. Zhang AS, West AP, Jr, Wyman AE et al. Interaction of hemojuvelin with neogenin results in iron accumulation in human embryonic kidney 293 cells. J Biol Chem 2005; 280: 33885-33894
135. Lin L, Goldberg YP, Ganz T. Competitive regulation of hepcidin mRNA by soluble and cell-Associated hemojuvelin. Blood 2005; 106: 2884-2889
136. Zhang AS, Anderson SA, Meyers KR et al. Evidence that inhibition of hemojuvelin shedding in response to iron is mediated through neogenin. J Biol Chem 2007; 282: 12547-12556
137. Chen W, Sun CC, Chen S et al. A novel validated enzyme-linked immunosorbent assay to quantify soluble hemojuvelin in mouse serum. Haematologica 2013; 98: 296-304
138. Gutiérrez OM, Sun CC, Chen W et al. Statement of concern about a commercial assay used to measure soluble hemojuvelin in humans. Am J Nephrol 2012; 36: 332-333
139. Malyszko J, Koc-Zórawska E, Levin-Iaina N et al. New parameters in iron metabolism and functional iron deficiency in patients on maintenance hemodialysis. Pol Arch MedWewn 2012; 122: 537-542
140. Lakhal S, Talbot NP, Crosby A et al. Regulation of growth differentiation factor 15 expression by intracellular iron. Blood 2009; 113: 1555-1563
141. Theurl I, Finkenstedt A, Schroll A et al. Growth differentiation factor 15 in anaemia of chronic disease, iron deficiency anaemia and mixed type anaemia. Br J Haematol 2010; 148: 449-455
142. Breit SN, Carrero JJ, Tsai VW et al. Macrophage inhibitory cytokine-1 (MIC-1/GDF15) and mortality in end-stage renal disease. Nephrol Dial Transplant 2012; 27: 70-75
143. Macdougall IC, Geisser P. Use of intravenous iron supplementation in chronic kidney disease: An update. Iran J Kidney Dis 2013; 7: 9-22
144. Fudin R, Jaichenko J, Shostak A et al. Correction of uremic iron deficiency anemia in hemodialyzed patients: A prospective study. Nephron 1998; 79: 299-305
145. Macdougall IC, Tucker B, Thompson J et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996; 50: 1694-1699
146. Markowitz GS, Kahn GA, Feingold RE et al. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Clin Nephrol 1997; 48: 34-40
147. Toblli JE, Cao G, Olivieri L et al. Comparison of the renal, cardiovascular and hepatic toxicity data of original intravenous iron compounds. Nephrol Dial Transplant 2010; 25: 3631-3640
148. Martin-Malo A, Merino A, Carracedo J et al. Effects of intravenous iron on mononuclear cells during the haemodialysis session. Nephrol Dial Transplant 2012; 27: 2465-2471
149. Wilson JG. Iron and glucose homeostasis: New lessons from hereditary haemochromatosis. Diabetologia 2006; 49: 1459-1461
150. Saeed O, Otsuka F, Polavarapu R et al. Pharmacological suppression of hepcidin increases macrophage cholesterol efflux and reduces foam cell formation and atherosclerosis. Arterioscler Thromb Vasc Biol 2012; 32: 299-307
151. Sazawal S, Black RE, Ramsan M et al. Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: Community-based, randomised, placebo-controlled trial. Lancet 2006; 367: 133-143
152. Boelaert JR, Vandecasteele SJ, Appelberg R et al. The effect of the host's iron status on tuberculosis. J Infect Dis 2007; 195: 1745-1753
153. McDermid JM, Jaye A, Schim Van Der Loeff MF et al. Elevated iron status strongly predicts mortality in West African adults with HIV infection. J Acquir Immune Defic Syndr 2007; 46: 498-507
154. Kuragano T, Shimonaka Y, Kida A et al. Determinants of hepcidin in patients on maintenance hemodialysis: Role of inflammation. Am J Nephrol 2010; 31: 534-540
155. Xiao JJ, Krzyzanski W, Wang YM et al. Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys. AAPS J 2010; 12: 646-657
156. Poli M, Girelli D, Campostrini N et al. Heparin: A potent inhibitor of hepcidin expression in vitro and in vivo. Blood 2011; 117: 997-1004
157. Sasu BJ, Cooke KS, Arvedson TL. Anti-hepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation induced anemia. Blood 2010; 115: 3616-3624
158. Hashizume M, Uchiyama Y, Horai N. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production. Rheumatol Int 2010; 30: 917-923
159. Sun CC, Vaja V, Chen S et al. A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats. Nephrol Dial Transplant 2013; 28: 1733-1743
160. Schwoebel F, Van Eijk LT, Zboralski D et al. The effects of the anti-hepcidin spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys. Blood 2013; 121: 2311-2315
161. Eli Lilly and Company. A phase 1 study of LY2787106 in cancer and anemia. http://clinicaltrials.gov/ct2/show/NCT01340976 (27 June 2013, date last accessed)
162. Eli Lilly and Company. A First Human Study of a Ferroportin Antibody. http://clinicaltrials.gov/ct2/show/NCT01330953 (27 June 2013, date last accessed)
163. Noxxon Pharma AG. Efficacy of NOX-H94 on anemia of chronic disease in patients with cancer. http://clinicaltrials.gov/ct2/show/NCT01691040 (27 June 2013, date last accessed)
164. FerruMax Pharmaceuticals, Inc. A phase 2A trial of FMX-8 treatment for anemia in patients with ESRD on hemodialysis HD. http://clinicaltrials. gov/ct2/show/NCT01873534 (27 June 2013, date last accessed)